Haleon achieved organic revenue growth of 6.8% in Q4 2024, driven by a combination of price and volume/mix improvements. The company's total revenue for the quarter reached £2.85 billion. Adjusted diluted EPS was 4.48p. The company saw continued strength in its Oral Health and Vitamins, Minerals, and Supplements (VMS) segments, while Pain Relief and Respiratory Health faced some headwinds.